A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
City of Hope Medical Center
University of Turin, Italy
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Mayo Clinic
Cancer Trials Ireland
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
The General Hospital of Western Theater Command
Affiliated Hospital to Academy of Military Medical Sciences
Alexion Pharmaceuticals, Inc.
Mayo Clinic
Gilead Sciences
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Alexion Pharmaceuticals, Inc.
European Myeloma Network B.V.
GlaxoSmithKline
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Augusta University
M.D. Anderson Cancer Center
Washington University School of Medicine
University of California, San Francisco
Peking University People's Hospital
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Celgene
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Affiliated Hospital to Academy of Military Medical Sciences
Massachusetts General Hospital
University of California, San Francisco
Dartmouth-Hitchcock Medical Center
Hackensack Meridian Health
Emory University
Essen Biotech
M.D. Anderson Cancer Center
Juno Therapeutics, a Subsidiary of Celgene
Mayo Clinic
University of Arkansas
Medical College of Wisconsin
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center